A 20% dose reduction of the original CISCA/VB regimen allows better tolerance and similar survival rate in disseminated testicular non-seminomatous germ-cell tumors: Final results of a phase III randomized trial

K. Fizazi, K. A. Do, X. Wang, L. Finn, C. J. Logothetis, R. J. Amato

Research output: Contribution to journal › Article › peer-review

20 Scopus citations

Fingerprint

Dive into the research topics of 'A 20% dose reduction of the original CISCA/VB regimen allows better tolerance and similar survival rate in disseminated testicular non-seminomatous germ-cell tumors: Final results of a phase III randomized trial'. Together they form a unique fingerprint.

Medicine & Life Sciences